Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.57 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.57 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LIG1 | P18858 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905536 | 0.85 | TSHR (0.42) | ERN1TLR2TLR1TLR6HPGD | |
| SCHEMBL28376944 | 0.84 | ERN1 (0.54) | ERN1TLR2TLR1TLR6HPGD | |
| SCHEMBL1482988 | 0.82 | ALDH1A1 (0.68) | HPGDTSHRMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL29690311 | 0.82 | ALDH1A1 (0.68) | HPGDTSHRMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL14507606 | 0.82 | ERN1 (0.65) | ERN1TLR2TLR1TLR6HPGD | |
| SCHEMBL3944635 | 0.81 | HPGD (0.49) | ERN1TLR2TLR1TLR6HPGD | |
| SCHEMBL978930 | 0.80 | HPGD (0.50) | HPGDTSHRMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL3967770 | 0.80 | HPGD (0.47) | ERN1TLR2TLR1TLR6HPGD | |
| SCHEMBL2522004 | 0.80 | HPGD (0.47) | ERN1TLR2TLR1TLR6HPGD | |
| SCHEMBL28190797 | 0.80 | HPGD (0.47) | ERN1TLR2TLR1TLR6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108358761-B | Salvianolic acid A intermediate and preparation method thereof | 上海交通大学 | 2020-11-06 | — | — | CN | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1601348-A4 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070123503-A1 | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases | EUKARION, INC. | 2007-05-31 | — | — | US | disclosed |
| US-7122537-B2 | Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases | EUKARION, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1688425-A2 | Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases | EUKARION, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1349864-B1 | CYCLIC SALEN-METAL COMPOUNDS AS SCAVENGERS FOR OXYGEN RADICALS AND USEFUL AS ANTIOXIDANTS IN THE TREATMENT AND PREVENTION OF DISEASES | EUKARION INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040059107-A1 | Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases | EUKARION, INC. | 2004-03-25 | — | — | US | disclosed |
| EP-1349864-A2 | CYCLIC SALEN-METAL COMPOUNDS AS SCAVENGERS FOR OXYGEN RADICALS AND USEFUL AS ANTIOXIDANTS IN THE TREATMENT AND PREVENTION OF DISEASES | EUKARION, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-6589948-B1 | Salen-metal compound having the following structure: manganese complex | EUKARION, INC. | 2003-07-08 | — | — | US | disclosed |
| WO-2002044187-A2 | CYCLIC SALEN-METAL COMPOUNDS AS SCAVENGERS FOR OXYGEN RADICALS AND USEFUL AS ANTIOXIDANTS IN THE TREATMENT AND PREVENTION OF DISEASES | EUKARION, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | ERN1 3895/4885TLR2 4556/4885TLR1 4497/4885 |
| US-20040059107-A1 | Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases | CAT, SOD3, SOD1 | ERN1 3681/4885TLR2 3720/4885TLR1 2790/4885 |
| US-20070123503-A1 | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases | CAT, SOD3, SOD1 | ERN1 3558/4885TLR2 3780/4885TLR1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.